Learn More
Invitrogen™ Phospho-p38 MAPK (Thr180, Tyr182) Monoclonal Antibody (4NIT4KK), PE, eBioscience™, Invitrogen™

Description
Description: This 4NIT4KK monoclonal antibody recognizes human and mouse p38 mitogen-activated protein kinase (MAPK) when phosphorylated on T180/Y182. p38 MAPK belongs to a family of conserved serine/threonine protein kinases that are phosphorylated and activated in response to numerous stress stimuli including TLR ligands (such as LPS), osmotic shock, heat shock, UV irradiation, and inflammatory cytokines. There are four p38 MAPK members that include p38 alpha, p38 beta, p38 gamma, and p38 delta. The primary activators of p38 MAPK are MKK3/4 and MKK6. Several downstream targets of p38 MAPK have been identified including MK2/3, p53, ATF-2, and ETS1. p38 MAPK can be negatively regulated by the chemical inhibitor SB203580. Specificity of this 4NIT4KK clone was determined by ELISA, flow cytometry, and western blotting. Applications Reported: This 4NIT4KK antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This 4NIT4KK antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.06 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Specifications
Specifications
| Antigen | Phospho-p38 MAPK (Thr180, Tyr182) |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | 4NIT4KK |
| Concentration | 5 μL/Test |
| Conjugate | PE |
| Formulation | PBS with BSA and 0.09% sodium azide; pH 7.2 |
| Gene | MAPK14 |
| Gene Accession No. | P47811, Q16539 |
| Gene Alias | Crk1; CSAID-binding protein; Csaids binding protein; CSBP; CSBP1; CSBP2; CSPB1; cytokine suppressive anti-inflammatory drug binding protein; cytokine suppressive anti-inflammatory drug binding protein 1; cytokine suppressive anti-inflammatory drug-binding protein; cytokine-supressive anti-inflammatory drug binding protein; Exip; Hog; MAP kinase 11; MAP kinase 13; MAP kinase 14; MAP kinase 2; MAP kinase Mxi2; MAP kinase p38 alpha; MAP kinase p38 beta; MAP kinase p38 delta; MAPK 11; MAPK 13; MAPK 14; Mapk11; Mapk13; MAPK-13; Mapk14; MAX-interacting protein 2; mitogen activated protein kinase 11; mitogen activated protein kinase 13; mitogen activated protein kinase 14; mitogen-activated protein kinase 11; Mitogen-activated protein kinase 13; mitogen-activated protein kinase 14; mitogen-activated protein kinase 14A; mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase p38 beta; mitogen-activated protein kinase p38 delta; mitogen-activated protein kinase p38-2; MXI2; p38; p38 alpha; p38 delta MAP kinase; p38 MAP kinase; p38 MAP kinase alpha; p38 MAPK; p38 mitogen activated protein kinase; p38-2; p38a; p38ALPHA; p38-alpha; p38alpha Exip; P38b; p38Beta; p38beta2; p38delta; p38Hog; p38MAPK; Prkm11; PRKM13; PRKM14; Prkm15; protein kinase, mitogen activated kinase, 11, p38beta; reactive kinase; RK; SAPK/Erk/kinase 4; SAPK2; SAPK2A; SAPK2B; SAPK4; Serk4; Stress-activated protein kinase 2a; Stress-activated protein kinase 2b; Stress-activated protein kinase 4; stress-activated protein kinase-2; stress-activated protein kinase-2b; tRNA synthetase cofactor p38 |
| Show More |
Frequently Asked Questions (FAQs)
Antibodies are tested and validated in a variety of ways. First, we verify that in a panel of cells in which different pathways have been induced, we see phosphorylation specific staining only in the cells in which the specific pathway of interest has been activated. Second, we verify that phosphorylation specific staining is observed only in cell types in which the protein is expressed and not in cell types in which the protein is not expressed. Third, whenever possible, western immunoblotting is used to confirm the presence of a band(s) of the appropriate size(s) in stimulated/treated cells (and not in unstimulated/untreated cells, as appropriate).
We have data demonstrating that fixed cells stored in methanol are stable at -20 degrees C or at -80 degrees C for several weeks. We do not recommend storing fixed cells in eBioscience Foxp3/Transcription Factor Buffer. However, cells fixed with eBioscience Foxp3/Transcription Factor Buffer or eBioscience Intracellular (IC) fixation buffer can be stored in eBioscience IC fixation buffer for up to 3 days at 4 degrees C in the dark.
Note: Please be aware that higher compensation values may be seen with tandem dyes if any other fixative is used apart from eBioscience IC fixation buffer, for 3-day storage.
Each antibody has been tested in three different buffer systems: IC fixation and permeabilization, Foxp3/Transcription Factor Buffer, and IC fixation Buffer/Methanol. The recommended buffer system(s) will be noted on the Technical Data Sheet for the specific antibody.
Because methanol can destroy the epitope recognized by some antibodies, ideally surface staining would be performed at the beginning of the protocol with a methanol-resistant fluorochrome (like eFluor 450, FITC, and eFluor 660).
Please recognize that surface staining before stimulation can have undesired effects due to activation of the cell caused by antibody binding. We recommend staining after stimulation/treatment, fixation, and methanol treatment.
In general, you can use other companies' buffer systems provided that their buffers are of a similar composition as the buffers recommended. Be aware that results will vary depending upon the buffer system used. eBioscience antibodies have been optimized for use in eBioscience buffers and we have not tested all of our antibodies in other buffer systems. Thus, we highly recommend using our optimized protocol and buffer systems.
Safety and Handling
For Research Use Only.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.